Romidepsin, a second HDAC inhibitor, was previously approved in 2011 for R/R PTCL but has since had its accelerated approval voluntarily withdrawn based on a negative phase III trial in upfront PTCL, though the agent is still available for use [15]. The gene discussed is HDAC9; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.